Galapagos
- Country
- π§πͺBelgium
- Ownership
- Public
- Established
- 1999-01-01
- Employees
- 1.1K
- Market Cap
- $1.9B
- Website
- http://www.glpg.com
- Introduction
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.
A Study With GLPG1972 in Osteoarthritis Subjects
- Conditions
- Osteoarthritis
- Interventions
- Drug: PlaceboDrug: GLPG1972 cohort 1Drug: GLPG1972 cohort 2Drug: GLPG1972 cohort 3
- First Posted Date
- 2017-10-16
- Last Posted Date
- 2017-11-24
- Lead Sponsor
- Galapagos NV
- Target Recruit Count
- 30
- Registration Number
- NCT03311009
- Locations
- πΊπΈ
Covance Daytona Beach, Daytona Beach, Florida, United States
A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG2451 in Healthy Male Subjects
- Conditions
- Healthy
- Interventions
- Drug: GLPG2451/GLPG2222 multiple doseDrug: Combined Placebo multiple doseDrug: GLPG2451 multiple doseDrug: Placebo multiple dose
- First Posted Date
- 2017-07-11
- Last Posted Date
- 2017-09-13
- Lead Sponsor
- Galapagos NV
- Target Recruit Count
- 39
- Registration Number
- NCT03214614
- Locations
- π§πͺ
SGS LSS Clinical Pharmacology Unit Antwerp, Antwerp, Belgium
Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Inflammatory Bowel Disease
- Conditions
- Inflammatory Bowel Disease
- Interventions
- First Posted Date
- 2017-06-28
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Galapagos NV
- Target Recruit Count
- 139
- Registration Number
- NCT03201445
- Locations
- πΊπΈ
University of Miami Crohn's and Colitis Center, Miami, Florida, United States
πΊπΈOne Health Research Clinic, Inc, Norcross, Georgia, United States
πΊπΈTexas Clinical Research Institute, Arlington, Texas, United States
Study to Compare Bioavailability of GLPG1972 Given as 2 Different Tablet Formulations Versus an Oral Solution
- Conditions
- Healthy
- Interventions
- Drug: GLPG1972
- First Posted Date
- 2017-05-08
- Last Posted Date
- 2017-06-20
- Lead Sponsor
- Galapagos NV
- Target Recruit Count
- 12
- Registration Number
- NCT03143725
- Locations
- π§πͺ
SGS Belgium Life Sciences, Antwerp, Belgium
Study to Assess Bioavailability of GLPG1690 Given as Oral Capsule or Tablet
- Conditions
- Healthy
- Interventions
- Drug: GLPG1690
- First Posted Date
- 2017-05-08
- Last Posted Date
- 2017-06-20
- Lead Sponsor
- Galapagos NV
- Target Recruit Count
- 12
- Registration Number
- NCT03143712
- Locations
- π§πͺ
SGS CPU, Antwerp, Belgium
A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG3067 in Healthy Subjects.
- Conditions
- Healthy
- Interventions
- Drug: GLPG3067 oral tabletDrug: Placebo single doseDrug: Placebo multiple doseDrug: GLPG3067/GLPG2222 multiple doseDrug: GLPG3067 single doseDrug: GLPG3067 oral suspensionDrug: GLPG3067 multiple doseDrug: GLPG3067/GLPG2222/GLPG2737 multiple doseDrug: GLPG3067/GLPG2222/GLPG2737 Placebo multiple doseDrug: GLPG3067/GLPG2222 Placebo multiple dose
- First Posted Date
- 2017-04-25
- Last Posted Date
- 2018-04-10
- Lead Sponsor
- Galapagos NV
- Target Recruit Count
- 81
- Registration Number
- NCT03128606
- Locations
- π§πͺ
SGS LSS Clinical Pharmacology Unit Antwerp, Antwerp, Belgium
A Study to Evaluate Multiple Doses of GLPG2222 in Adult Subjects With Cystic Fibrosis
- Conditions
- Cystic Fibrosis
- Interventions
- Drug: GLPG2222 50 mgDrug: GLPG2222 100 mgDrug: GLPG2222 400 mgDrug: PlaceboDrug: GLPG2222 200 mg
- First Posted Date
- 2017-04-18
- Last Posted Date
- 2018-11-16
- Lead Sponsor
- Galapagos NV
- Target Recruit Count
- 59
- Registration Number
- NCT03119649
- Locations
- πΊπΈ
University of Arkansas for medical Sciences, Little Rock, Arkansas, United States
πΊπΈMaine Medical Center, Portland, Maine, United States
πΊπΈMedical University of South Carolina, Charleston, South Carolina, United States
A Study to Assess Efficacy and Safety of Filgotinib in Ankylosing Spondylitis
- Conditions
- Ankylosing Spondylitis
- Interventions
- Drug: Placebo Oral TabletDrug: filgotinib
- First Posted Date
- 2017-04-17
- Last Posted Date
- 2018-08-13
- Lead Sponsor
- Galapagos NV
- Target Recruit Count
- 116
- Registration Number
- NCT03117270
- Locations
- π΅π±
Centrum Medyczne SILESIANA Sp z oo, Bytom, Poland
πΊπ¦SI NSΠ‘ M.D. Strazhesko Institute of Cardiology of NAMSU, Unit of Non-coronary HD&Rh, Kiev, Ukraine
πΊπ¦CH of State Border Service of Ukraine (Military Base 2522) Dept of Therapy, D.Halytskyi Lviv NMU, Ch of Family Medicine & Dermatology, Venereology, L'viv, Ukraine
This is a Study to Evaluate the Effect of Aging of Multiple Doses of GLPG1205 in Healthy Subjects
- Conditions
- ElderlyHealthy
- Interventions
- Drug: Placebo oral capsuleDrug: GLPG1205 250 loading dose and 50mg q.d. maintenance doseDrug: GLPG1205 50mg q.d.
- First Posted Date
- 2017-04-05
- Last Posted Date
- 2017-04-05
- Lead Sponsor
- Galapagos NV
- Target Recruit Count
- 32
- Registration Number
- NCT03102567
- Locations
- π§πͺ
SGS clinical pharmacology unit, Antwerp, Belgium
A Study to Assess Efficacy and Safety of Filgotinib in Active Psoriatic Arthritis
- First Posted Date
- 2017-04-05
- Last Posted Date
- 2018-04-23
- Lead Sponsor
- Galapagos NV
- Target Recruit Count
- 131
- Registration Number
- NCT03101670
- Locations
- πͺπΈ
Hospital Infanta Luisa, Servicio de Reumatologia, Sevilla, Spain
π§π¬MHAT - Ruse, AD, Ruse, Bulgaria
π¨πΏCCBR Czech, a.s, Pardubice, Czechia